Overview
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
Status:
Completed
Completed
Trial end date:
2020-04-26
2020-04-26
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
AbbVieTreatments:
Antibodies, Monoclonal
Criteria
Inclusion Criteria:- Body Mass Index (BMI) is >= 19.0 to <= 26.0 kg/m2 after rounding to the nearest tenth.
BMI is calculated as weight in kg divided by the square of height measured in meters.
Exclusion Criteria:
- Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.